In conclusion, our study demonstrated that plasma EGFR mutation detection by ddPCR is feasible and effective in monitoring treatment response and resistance to EGFR-TKIs in NSCLC patients under certain conditions. Here, EGFR is linked to non-small cell lung carcinoma.